Alpha 2.0
Login Register
» Authors » Christopher H Hawkes

Christopher H Hawkes

Explore the profile of Christopher H Hawkes including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 56
Citations 1360
Followers 0
Related Specialties
Neurology
General Medicine
Psychiatry
Top 10 Co-Authors
Gavin Giovannoni
Michael Levy
Jeannette Lechner-Scott
E Ann Yeh
Jeanette Lechner-Scott
Ann Yeh
Emmanuelle Waubant
Daniela Pohl
Anette Schrag
Alastair J Noyce
Published In
Mult Scler Relat Disord
Mov Disord
Parkinsonism Relat Disord
Pract Neurol
Ann N Y Acad Sci
Affiliations
Soon will be listed here.
Recent Articles
1.
Infectious mononucleosis is a more realistic target for preventing multiple sclerosis
Giovannoni G, Hawkes C, Lechner-Scott J, Yeh E, Levy M
Mult Scler Relat Disord . 2025 Feb; 95:106337. PMID: 39986138
There is compelling epidemiological evidence that prior infection with Epstein-Barr virus (EBV) is necessary to develop multiple sclerosis (MS). That people who are EBV-negative are protected from getting MS underpins...
2.
Potential mechanisms of how B-cell depletion works in MOGAD
Bilodeau P, Yeh A, Lechner-Scott J, Hawkes C, Giovannoni G, Levy M
Mult Scler Relat Disord . 2025 Jan; 93:106269. PMID: 39827742
No abstract available.
3.
Smouldering-associated worsening or SAW: the next therapeutic challenge in managing multiple sclerosis
Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Yeh E
Mult Scler Relat Disord . 2024 Dec; 92:106194. PMID: 39626477
No abstract available.
4.
FROM BENCH TO BEDSIDE: A SNAIL IN TREACLE?
Hawkes C, Giovannoni G, Lechner-Scott J, Levy M, Yeh A
Mult Scler Relat Disord . 2024 Oct; 91:105916. PMID: 39406046
No abstract available.
5.
Can placebo-controlled phase 2 disease-modifying therapy trials in MS still be justified?
Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Yeh E, Pepper G, et al.
Mult Scler Relat Disord . 2024 Jun; 87:105698. PMID: 38850685
No abstract available.
6.
Open access publishing and the future of scientific communication
Hawkes C, Giovannoni G, Lechner-Scott J, Levy M, Yeh A
Mult Scler Relat Disord . 2024 Apr; 86:105625. PMID: 38626688
No abstract available.
7.
In the era of antiviral trials for MS, the answer lies in the details
Drosu N, Bjornevik K, Bilodeau P, Yeh A, Lechner-Scott J, Hawkes C, et al.
Mult Scler Relat Disord . 2024 Jan; 82:105444. PMID: 38241758
No abstract available.
8.
Emboldened or not: The potential fall-out of a failed anti-EBV trial in multiple sclerosis
Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Yeh E
Mult Scler Relat Disord . 2023 Dec; 81:105364. PMID: 38104476
No abstract available.
9.
Is multiple sclerosis a glymphaticopathy?
Alghanimy A, Giovannoni G, Lechner-Scott J, Levy M, Yeh E, Hawkes C
Mult Scler Relat Disord . 2023 Dec; 80:105141. PMID: 38039696
No abstract available.
10.
CNS resilience in the progression of MS
Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Yeh E
Mult Scler Relat Disord . 2023 Aug; 77:104937. PMID: 37634271
Resilience; Progressive multiple sclerosis; Genomics.